QNCX Investor Conference discussion. September 9th.

{"summary": "Commenter gives a bullish analysis of QNCX (Quince Therapeutics) citing LAM-001's differentiated lung transplant treatment, surgeon endorsement, financing runway to 2028, and completed dilution.", "reason": "Author gives own long judgment on QNCX with fundamental rationale (LAM-001 unmet need, surgeon endorsement, data, runway) and verbatim supporting quote.", "ideas": [{"symbol": "QNCX", "direction": "long", "thesis": "The author argues QNCX's LAM-001 addresses an unmet need in reaching deep lung tissue for transplant patients, with a once-daily formulation requiring no medical supervision and vocal endorsement from top US transplant surgeons who say such a treatment has been needed for a decade. They cite improved lung function data post-transplant, financing runway until 2028, and completed dilution as supporting factors. Downside is seen near $20 with upside potentially around $185, though the author frames this as an unchecked personal estimate rather than a firm target.", "thesis_short": "QNCX LAM-001 lung transplant opportunity undervalued", "quote": "Based on the unmet needs vs outcome vs efficiency of reaching the deep tissue of the lungs, while others seem to lack this.", "confidence": 0.65, "sentiment": 0.7, "timeframe": "1 year"}], "model": "deepseek-v4-flash", "verified": true, "extraction_model": "deepseek-v4-flash"}